Despite many years of research, the only drug licensed for the radical cure and relapse prevention of P. vivax, primaquine, can trigger severe hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals, making it necessary to test a patient for this common genetic disorder that is quite common in endemic areas, before prescribing the drug [8]. Here, G6PD is linked to hereditary disease.